Potential Treatment of Steroid-Resistant Alopecia Areata Using Allogeneic Exosomes Derived From Adipose Tissue Mesenchymal Stromal Cells: A Case Report.

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

A 31-year-old man with severe, corticosteroid-resistant alopecia areata presented with substantial scalp hair loss (Severity of Alopecia Tool [SALT] score: 60%) despite a 1-year regimen of topical corticosteroids, 5% minoxidil, and oral prednisolone. He was treated with allogeneic exosomes derived from adipose tissue mesenchymal stromal cells (ADMSCs-Exo) at 3-week intervals over 12 weeks (four sessions; 10 12 particles each). A cessation of hair shedding was noted after the initial session, followed by progressive regrowth that led to near-complete hair restoration by Week 12. Treatment was accompanied by an increase in anti-inflammatory cytokines (IL-4, IL-6, IL-10) and a reduction of IFN-γ, TNF-α, and IL-17 toward baseline levels. No adverse effects were reported during active treatment or throughout the 18-week posttreatment follow-up period. While limited to a single patient, this case suggests that ADMSC-derived exosomes warrant further investigation as a potential cell-free therapeutic option for refractory alopecia areata.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.